

**SAUL EWING  
ARNSTEIN  
& LEHR**<sup>LLP</sup>

Charles M. Lizza  
Phone: (973) 286-6715  
Fax: (973) 286-6815  
[clizza@saul.com](mailto:clizza@saul.com)  
[www.saul.com](http://www.saul.com)

April 7, 2022

**VIA ECF**

The Honorable Leda D. Wettre, U.S.M.J.  
United States District Court  
King Fed. Bldg. & U.S. Courthouse  
50 Walnut Street  
Newark, New Jersey 07101

Re: *Celgene Corporation v. Alembic Pharmaceuticals Limited*  
Civil Action No. 21-20099 (SDW)(LDW)

Dear Judge Wettre:

This firm, together with Quinn Emanuel Urquhart & Sullivan, LLP and Jones Day, represents plaintiff Celgene Corporation in the above-captioned matter.

Enclosed is a copy of the parties' proposed Discovery Confidentiality Order ("DCO"). If this meets with the Court's approval, we respectfully request that Your Honor execute the proposed DCO and have it entered on the docket.

Thank you for Your Honor's kind attention to this matter.

Respectfully yours,



Charles M. Lizza

Enclosure

cc: All Counsel (via e-mail)

Charles M. Lizza  
William C. Baton  
Sarah A. Sullivan  
SAUL EWING ARNSTEIN & LEHR LLP  
One Riverfront Plaza, Suite 1520  
Newark, New Jersey 07102-5426  
(973) 286-6700  
[clizza@saul.com](mailto:clizza@saul.com)

*Attorneys for Plaintiff  
Celgene Corporation*

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY**

---

**CELGENE CORPORATION,**  
**Plaintiff,**  
**v.**  
**ALEMBIC PHARMACEUTICALS**  
**LIMITED,**  
**Defendant.**

---

**Civil Action No. 21-20099  
(SDW)(LDW)**

**PROPOSED STIPULATED  
DISCOVERY CONFIDENTIALITY  
ORDER**

**(Filed Electronically)**

**WHEREAS**, Plaintiff Celgene Corporation (“Plaintiff” or “Celgene”) and Defendant Alembic Pharmaceuticals Limited (“Alembic”) are the parties to Civil Action No. 21-20099 (SDW)(LDW) (the “action” or “litigation”);

**WHEREAS**, the parties to this action believe that one or more of them will or may be required to disclose to another party certain documents, things, and information that constitute or contain trade secrets, technical know-how, or other confidential or proprietary research, development, business, commercial, or financial information relating to the subject matter of this action;

**WHEREAS**, the parties consider such information to be confidential and proprietary within the meaning of Fed. R. Civ. P. 26(c)(1)(G), *Pansy v. Borough of Stroudsburg*, 23 F.3d 772 (3d Cir. 1994) and *Glenmede Trust Co. v. Thompson*, 56 F.3d 476 (3d Cir. 1995) and, therefore, mutually desire that a Discovery Confidentiality Order limiting use, access to, and disclosure of such information be entered;

**WHEREAS**, to preserve the legitimate business interests of the parties or nonparties in their confidential information without unduly encroaching upon the public’s right to be informed of judicial proceedings in accordance with Local Civil Rule 5.3;

**WHEREAS**, a party seeking to protect information filed under seal with the Court must show good cause for sealing that part of the record, in accordance with Local Civil Rule 5.3;

**WHEREAS**, the parties contemplate that confidential information produced in this action may be produced by a nonparty, and the parties also seek to facilitate the production and protection of such confidential information;

**WHEREAS**, the parties have exchanged and/or expect to exchange discovery in connection with this matter and recognize that confidential information may be disclosed in the course of this discovery, and in other proceedings in this matter;

**WHEREAS**, the parties desire to limit the extent of disclosure and use of such confidential information, and to protect such confidential information from unauthorized use and/or further disclosure, and wish to ensure that no advantage is gained by any party by the use of such confidential information which could not have been gained had discovery in this action not occurred;

**WHEREAS**, this action involves highly technical subject matter requiring discovery of trade secrets and proprietary information pertaining to, among other things, drug formulations, manufacturing processes and techniques, scientific research and development, and other sensitive competitive information; and

**WHEREAS**, the parties have consented to the entry of this Discovery Confidentiality Order pursuant to Fed. R. Civ. P. 26(c)(1)(G) and Local Civil Rule 5.3 and the Court having considered the foregoing and for good cause shown,

**IT IS** on this \_\_\_\_\_ day of \_\_\_\_\_, 2022,

**ORDERED**, that the following provisions shall govern the conduct of further proceedings in this action:

**Definitions**

1. (a) The term “Confidential Information” shall mean any tangible thing or oral testimony that contains or reveals what a party or nonparty considers to be its trade secret, business confidential, or proprietary information. It may include, without limitation, documents produced in this action, during formal discovery or otherwise; information of nonparties which the producing or designating party is under an obligation to maintain in confidence; initial disclosures; answers

to interrogatories and responses to requests for admission or other discovery requests; deposition or hearing transcripts; affidavits; exhibits; experts' reports; memoranda of law; and tangible things or objects that are designated Confidential pursuant to this Order. The information contained therein and all copies, abstracts, excerpts, analyses, notes or other writings that contain, reflect, reveal or otherwise disclose such confidential information shall also be deemed "Confidential Information." Information originally designated as "Confidential Information" shall not retain that status after any ruling by the Court denying such status to it. Each party shall act in good faith in designating information as "Confidential Information."

(b) The term "Highly Confidential Information" shall mean all information regarding (i) confidential and/or proprietary information pertaining to marketing, sales, revenues, profits, forecasts, or business plans or strategies for any existing products or products in development; (ii) past, current, or future products other than lenalidomide-containing drug products; (iii) past, current, or future plans regarding treatment indications for lenalidomide-containing drug products other than the treatment indications for which United States Food and Drug Administration ("FDA") approval is or has been sought; and (iv) scientific, regulatory, or technical information relating to, referring to, or concerning (but excluding publicly available scientific information and publications) Revlimid®, Celgene's NDA 21-880, Alembic's ANDA No. 216260, DMF No. 034650 and/or any associated products. It may include, without limitation, documents produced in this action, during formal discovery or otherwise; information of non-parties which the producing or designating party is under an obligation to maintain in confidence; initial disclosures; answers to interrogatories and responses to requests for admission or other discovery requests; deposition or hearing transcripts; affidavits; exhibits; experts' reports; memoranda of law; and tangible things or objects that are designated Highly Confidential pursuant

to this Order. The information contained therein and all copies, abstracts, excerpts, analyses, notes, or other writings that contain, reflect, reveal, or otherwise disclose such highly confidential information shall also be deemed “Highly Confidential Information.” Information originally designated as “Highly Confidential Information” shall not retain that status after any ruling by the Court denying such status to it. Each party shall act in good faith in designating information as “Highly Confidential Information.”

- (c) The term “party” means Celgene and/or Alembic.
- (d) The term “producing party” means the party or nonparty producing documents or information as Confidential Information or Highly Confidential Information under this Order.
- (e) The term “receiving party” shall mean the party to whom Confidential Information or Highly Confidential Information is produced.

**Designation of Confidential Information and Highly Confidential Information**

2. Each producing party who produces or discloses any material that it believes comprises Confidential Information may so designate it by marking the document, information, thing, or portion thereof containing the information “CONFIDENTIAL.” Each producing party who produces or discloses any material that it believes comprises Highly Confidential Information may so designate it by marking the document, information, thing, or portion thereof containing the information “HIGHLY CONFIDENTIAL.” When documents are produced for inspection, the documents shall be treated by the receiving party as “Highly Confidential” until copies are provided. Deposition testimony will be treated as Highly Confidential Information unless otherwise designated, confidentiality is waived or reduced either on the record during the deposition or within twenty-five (25) calendar days after receipt of the transcript, or the court orders that such testimony is not Highly Confidential. Each transcript shall be prominently marked

on the front page with a statement that provides “THIS DEPOSITION TRANSCRIPT CONTAINS [HIGHLY] CONFIDENTIAL INFORMATION SUBJECT TO DISCOVERY CONFIDENTIALITY ORDER” or similar legend. For non-written material, such as recordings, magnetic media, photographs, and things, a legend substantially in the above form shall be affixed to the material, or a container for it, in any suitable manner.

3. If any Confidential Information or Highly Confidential Information is produced by a nonparty to this litigation, such a nonparty shall be considered a producing party within the meaning of that term as it is used in the context of this Order and each of the parties shall be treated as a receiving party. Confidential Information or Highly Confidential Information that originated with a nonparty may be designated as such and shall be subject to the restrictions on disclosure specified herein.

4. In the event any producing party produces Confidential Information or Highly Confidential Information that has not been designated as such or not correctly designated, the producing party may designate or redesignate the information to the same extent as it may have designated the information before production, by a subsequent notice in writing specifically identifying the redesignated information, in which event the parties shall henceforth treat such information in accord with this Order, and shall undertake their best efforts to correct any disclosure of such information contrary to the redesignation, including retrieving any documents from persons not qualified to receive them under the redesignation and informing such persons that they should not further use or disseminate the information thereon. No demonstration or proof of error, inadvertence, or excusable neglect by the designating party shall be required for such redesignation, with the following exception: corrections to the designation of documents or information used in hearings, depositions, and trial must be made contemporaneously or else are

waived, but only in situations where the nature of the hearing, deposition, or trial would otherwise be inconsistent with the designation sought (by way of nonlimiting example, redesignation must be contemporaneous in a public hearing where a party seeks to designate a document as “Confidential” or “Highly Confidential,” but redesignation need not be contemporaneous in a sealed hearing where a party seeks to designate a document as “Confidential” or “Highly Confidential”).

**Challenge to Designation**

5. A party shall not be obligated to challenge the propriety of any designation of Confidential Information or Highly Confidential Information at the time the designation is made, and failure to do so shall not preclude a subsequent challenge to the designation. In the event that any party to this action disagrees at any stage of this action with any designation, such party shall provide written notice of its disagreement with the designation to the producing party. The parties shall first try to dispose of such dispute in good faith on an informal basis without judicial involvement. If the dispute cannot be resolved, the party challenging the designation may request appropriate relief from the Court within ten (10) business days after written notice is provided, provided such request is in accordance with Local Civil Rule 37.1. The burden of proving that information has been properly designated is on the producing party. However, the parties agree that designating information as Confidential Information or Highly Confidential is improper if such information (i) can be shown to be generally available to the public at the time of such designation; (ii) becomes part of the public domain or publicly known or available by publication or otherwise not as the result of any unauthorized act or omission on the part of the non-designating party; or (iii) is thereafter disclosed to the non-designating party by a third party as a matter of right.

**Disclosure and Use of Confidential Information and Highly Confidential Information**

6. (a) Subject to Paragraphs 10-14, Confidential Information of the producing party may be disclosed, summarized, described, revealed, or otherwise made available in whole or in part only in accordance with the terms of this Order, and only to the following persons:

(i) outside counsel of record for Celgene and Alembic, and employees of such counsel, who, after receipt of Confidential Information, and in addition to the other terms of this Discovery Confidentiality Order, shall not use any other party's or any nonparty's Confidential Information for any purpose other than in connection with this litigation, and shall not disclose any other party's or any nonparty's Confidential Information to any third party, including, but not limited to, the FDA and the United States Patent and Trademark Office ("PTO");

(ii) four (4) designated in-house attorneys or legal representatives employed by each party employed by each party, as well as their clerical staff (including paralegals), who have a need to know Confidential Information to fulfill their duties and responsibilities in connection with this litigation, provided such attorneys or legal representatives have complied with Paragraph 12 hereof, the designated in-house attorneys or legal representatives for the parties being as follows:

For Celgene: to be determined;

For Alembic: to be determined;

who, after receipt of Confidential Information, and in addition to the other terms of this Discovery Confidentiality Order, shall not use any other party's or any nonparty's Confidential Information for any purpose other than in connection with this litigation, and shall not disclose any other party's or any nonparty's Confidential Information to any third party, including, but not limited to, the FDA and the PTO;

(iii) two (2) employees of a receiving party and their immediate support staff, who have a need to know Confidential Information to fulfill their duties and responsibilities, but who shall not have direct responsibility for competitive decision-making regarding compounds or compositions containing lenalidomide, provided that the employees and parties have complied with the procedures set forth in Paragraphs 12-14 hereof;

(iv) independent experts and consultants and their staff (excluding current and former directors and officers or employees of the parties) retained to assist counsel for the parties in the conduct of this litigation, provided such persons have complied with Paragraph 12 hereof;

(v) potential fact witnesses in this action who are currently directors, officers, employees, or corporate designees of the producing party under Fed. R. Civ. P. 30(b)(6), but only at deposition or trial;

(vi) potential fact witnesses in this action (including, but not limited to, those who were formerly directors, officers, employees, or corporate designees of the producing party, but only for those witnesses if the Confidential Information was in existence during the period of his or her service or employment and foundation is established that the witness was involved in the project to which the Confidential Information relates so that it is reasonable that the witness had access to the Confidential Information during the course of his or her service or employment) and their counsel, provided that the information was authored by, created by, addressed to, received by, signed by, or is otherwise established to have been known to the witness; but only at deposition, trial, or court hearing, and the good faith preparation therefor;

(vii) the Court and its employees and the jury;

(viii) court reporters and videographers;

- (ix) photocopy services;
- (x) professional translators who are retained by the attorneys for the parties for the purposes of this litigation;
- (xi) graphics or design consultants retained to prepare demonstrative or other exhibits for use in this action;
- (xii) non-technical jury or trial consultants and persons employed or retained by them solely in providing litigation support services to the parties' outside counsel law firms;
- (xiii) document imaging and database services and consultants retained to set up, maintain and/or operate litigation databases for this litigation; and
- (xiv) any others as ordered by the Court or to whom the producing party has given written consent.

(b) Subject to Paragraphs 10-14, Highly Confidential Information of the producing party shall be subject to the same restrictions as Confidential Information set forth in Paragraph 6(a) except that it may be disclosed, summarized, described, revealed or otherwise made available in whole or in part only to the persons identified in Paragraphs 6(a)(i)-(ii) and (iv)-(xiv) and otherwise in accordance with the terms of this Order.

7. Nothing in this Discovery Confidentiality Order shall prevent disclosure of Confidential Information or Highly Confidential Information if the producing party consents to such disclosure or if the Court, after notice to all parties, orders such disclosure.

8. All Confidential Information and Highly Confidential Information disclosed pursuant to this Order shall be used by a recipient thereof solely for the purposes of this litigation and not for any business, regulatory, commercial, or competitive purposes, including, but not

limited to, filing or prosecuting patent applications, engaging in any post-grant patent proceeding, or any communicating or petitioning activity with the FDA or another regulatory agency. It shall be the duty of each party and each individual having notice of this Discovery Confidentiality Order to comply with this Order from the time of such notice. Subject to the other requirements of this Discovery Confidentiality Order, including this Paragraph 8, nothing herein shall prevent the individuals identified in Paragraph 6 from participating in any post-grant proceedings at the PTO or in any foreign patent office or tribunal (including, but not limited to, ex parte reexamination, *inter partes* review, post-grant review, covered-business-method review, patent opposition proceedings, patent nullity proceedings, or patent invalidation proceedings).

9. By written agreement of the parties, or upon motion and order of the Court, the list of individuals designated under Paragraph 6 to whom Confidential Information or Highly Confidential Information may be disclosed may be modified or expanded.

10. If a producing party seeks to protect Confidential Information or Highly Confidential Information from public disclosure or use during a trial, court appearance or hearing which is open to the public (a “Court Disclosure”), the producing party shall make an application to the Court to restrict such disclosure or use, unless consent from the receiving party is previously obtained. Such application may be made at any time before the Court Disclosure or within ten (10) business days after the Court Disclosure.

11. Any party filing any document, material or information designated by another party as “CONFIDENTIAL” or “HIGHLY CONFIDENTIAL” shall comply with Local Civil Rule 5.3(c) to seal such document, material or information to prevent public disclosure. In supplementation of Local Civil Rule 5.3(c)(4), (unless this procedure is obviated by the recently amended procedures requiring the filing of an omnibus motion to seal), before filing any redacted

public copy, a “proposed redacted copy” shall be provided to the opposing party(ies), reasonably in advance of the filing deadline and no later than 5:00 p.m. Eastern, to allow additional redactions to be designated and/or unnecessary redactions to be removed. The parties will work together in good faith to jointly prepare the motion and supporting documents required by Local Civil Rule 5.3(c)(3) and, should the need arise, will seek additional time to file any redacted public copy. Nothing in this provision relieves a party of liability for damages caused by the electronic filing of Confidential Information or for damages caused by failure to properly file under seal documents or materials containing Confidential Information or Highly Confidential Information.

12. No person identified in Paragraph 6(a)(ii)-(iv) shall be given access to Confidential Information and/or Highly Confidential Information unless such person shall first have signed a Declaration of Compliance with this Order in the form attached as Exhibit A hereto.

13. Before any person identified in Paragraphs 6(a)(ii)-(iv) may be given access to Confidential Information and/or Highly Confidential Information, the party seeking to provide such access shall deliver a copy of the Declaration referred to in Paragraph 12, fully executed by such person, and written notice (by email) to the attorneys for the producing party of the intention to make such disclosure. In the case of a disclosure to persons identified in Paragraph 6(a)(iv) hereof, the notice shall state the name and address of the person to whom disclosure is proposed and include a curriculum vitae and an identification of the person’s job title and responsibilities. In the case of a disclosure to persons identified in Paragraphs 6(a)(ii)-(iii) hereof, the notice shall state the individual’s name and position.

14. For proposed disclosures to persons identified in Paragraphs 6(a)(ii), (iii), and (iv), hereof, the producing party, within seven (7) business days from receiving service of written notice provided pursuant to Paragraph 13 hereof, may object to such disclosure by delivery (by email) of

a written notice of objection on the attorneys for the party seeking to make the disclosure, stating the reasons for the objection. No disclosure of Confidential Information or Highly Confidential Information may occur prior to the expiration of seven (7) business days from the date of service of the written notice of intent to disclose unless consent is granted earlier by the producing party or Ordered by the Court. Consent pursuant to the provisions of this Paragraph shall not be unreasonably withheld. If the producing party objects to the disclosure and gives written notice thereof, and the parties are unable to resolve the objection, the party opposing the disclosure must file a letter application to the Court pursuant to L. Civ. R. 37.1 within seven (7) business days of giving the written notice of objection; otherwise, the information may be disclosed to the identified person. If such an application is made, no disclosure may be made until the objection is resolved by agreement of the designating and receiving parties or the Court denies the application. Failure to timely object to the disclosure based on information then-disclosed in the written notice pursuant to Paragraph 13 hereof shall operate as a waiver of the objection. Waiver as to a specific disclosure shall not constitute waiver for any subsequent disclosures. In the event that an application is made, the objecting party shall have the burden of proving that disclosure should not occur.

15. Nothing herein shall prevent a producing party from disclosing its own Confidential Information or Highly Confidential Information in any manner that it considers appropriate.

16. Nothing herein shall bar or otherwise restrict counsel from rendering advice to his or her client with respect to this litigation and, in the course thereof, referring to or relying upon his or her examination of Confidential Information or Highly Confidential Information. In rendering such advice and in otherwise communicating with his or her client, counsel shall not disclose any Confidential Information or Highly Confidential Information if such disclosure would be contrary to the provisions of this Discovery Confidentiality Order.

17. If a party is served with a subpoena, discovery request in another action, or any other request seeking by legal process the production of documents, things, information or other material produced to it and designated as Confidential Information or Highly Confidential Information in this action, such party shall notify promptly the producing party so as to provide the producing party a reasonable opportunity to object to the production.

18. If an additional party joins or is joined in this action, the newly joined party shall not have access to Confidential Information and Highly Confidential Information until the parties agree to a supplemental Discovery Confidentiality Order governing the protection of Confidential Information and Highly Confidential Information.

19. Any third party from whom discovery is sought in this action may designate some or all of the documents, things, information or other material as Confidential Information and Highly Confidential Information under this Discovery Confidentiality Order. If it does so, then each party to the action will have with respect to such Confidential Information and Highly Confidential Information the same obligations which that party has with respect to Confidential Information and Highly Confidential Information of another party to this action.

**Duration of Order, Objections, Modifications**

20. This Discovery Confidentiality Order shall remain in force and effect indefinitely until modified, superseded or terminated by Order of this Court, which may be entered pursuant to agreement of the parties hereto. This Discovery Confidentiality Order shall continue in effect after termination of this action and continue to be binding upon all persons to whom Confidential Information or Highly Confidential Information is disclosed hereunder.

21. Upon final termination of this action (including all appeals) the receiving party shall, within sixty (60) calendar days of such termination, either return to the producing party or destroy all Confidential Information and Highly Confidential Information in its possession,

including, but not limited to, information stored in electronic form. In either event, the receiving party shall describe the materials returned or destroyed and certify their return or destruction, with the exception that outside counsel may retain subject to the provisions of this Discovery Confidentiality Order one copy of the pleadings or other papers filed with the Court or served in the course of the litigation, deposition transcripts, deposition exhibits, hearing transcripts, and any hearing or trial record (including without limitation all bench memoranda, PowerPoint slides, and exhibits).

22. If the receiving party desires to disclose Confidential Information or Highly Confidential Information to persons not qualified to receive it under this Order or if the receiving party disagrees with a designation by the producing party, then the receiving party and the producing party shall first try to resolve such dispute. If the dispute cannot be resolved, either party may seek a ruling from the Court. Pending a determination by the Court, such information shall be treated under this Order as Confidential Information or Highly Confidential Information as designated by the producing party.

**No Waiver of Privileges**

23. If information that is otherwise properly subject to a claim of attorney-client privilege, attorney work-product immunity, or any other privilege or immunity protecting it from discovery is inadvertently produced, the fact or circumstances of such inadvertent production shall in no way be relied upon as a ground to support any argument that the information is no longer subject to the privilege or immunity. Nor shall such inadvertent production prejudice or otherwise constitute a waiver of, or estoppel as to, any claim of privilege, work product immunity or other ground for withholding production to which the producing party or other person otherwise would be entitled, either in whole or in part, in this litigation or in any other proceeding. If a written claim of inadvertent production is made pursuant to this Paragraph, upon receipt of such written

notice, the receiving party shall promptly destroy or return to the producing party (i) the inadvertently produced material, (ii) any and all copies or reproductions thereof, and (iii) any and all copies of summaries or notes based thereon or relating thereto, of which the receiving party is aware.

24. However, if the receiving party wishes to challenge the claim that the information would have properly been subject to a privilege or immunity before it was inadvertently produced, it may retain one copy and must notify the producing party of its challenge within ten (10) business days of receiving the notice of inadvertent production, and move the Court for a ruling on the propriety of the claim of privilege or immunity within ten (10) business days of receiving the notice of inadvertent production, unless such time period is extended by mutual agreement of the parties. During the pendency of such motion, the receiving party may retain the single copy but shall make no other use or disclosure of the subject material or the information contained therein. The producing party shall bear the burden of proving that the inadvertently produced documents or materials are privileged or immune from discovery. Within five (5) business days of the receiving party's timely filing of an application pursuant to L. Civ. R. 37.1 seeking an order compelling production of the inadvertently produced documents or materials, the producing party shall provide to the Court's email address—LDW\_orders@njd.uscourts.gov—a copy of the inadvertently produced documents or materials for *in camera* inspection by the Court. A copy of the cover letter forwarding the inadvertently produced information for *in camera* inspection by the Court shall be provided to the moving party. If the receiving party prevails on its challenge to the producing party's claim of privilege or immunity, the producing party shall promptly reproduce the material to the receiving party. If the receiving party does not prevail on its challenge to the producing

party's claim of privilege or immunity, it must certify to the producing party within five (5) business days of the Court's decision that it has destroyed the remaining single copy.

25. If any Confidential Information or Highly Confidential Information is disclosed through inadvertence or otherwise by a receiving party to any person or party not otherwise authorized to receive such information under this Discovery Confidentiality Order, then the receiving party responsible for the disclosure shall (i) use its best efforts to obtain the return of such information and to bind such non-authorized person or party to the terms of this Discovery Confidentiality Order; (ii) within three (3) business days of the discovery of such disclosure, inform such person or party of all provisions of this Discovery Confidentiality Order and request that such person or party sign the Declaration of Compliance with this Discovery Confidentiality Order in the form attached as Exhibit A hereto; and (iii) within five (5) business days of the discovery of such disclosure, inform the producing party of all pertinent facts relevant to such disclosure, including the identity of such person or party and the information disclosed thereto.

**No Waiver of Right to Appropriately Withhold or Redact**

26. Notwithstanding the provisions of this Discovery Confidentiality Order, parties may redact from any document, whether or not designated Confidential Information or Highly Confidential Information under this Order, any information containing privileged material or material protected by work-product immunity.

**Amendment**

27. This Discovery Confidentiality Order may be amended with respect to (a) specific documents or items of Confidential Information or Highly Confidential Information, or (b) persons to whom Confidential or Highly Confidential Information may be disclosed, upon written agreement of the parties with the approval of the Court. This Discovery Confidentiality Order

shall remain in force and effect indefinitely until modified, superseded, or terminated by order of this Court.

**Other Remedies**

28. Nothing herein shall prevent any party or nonparty from seeking additional or different relief from the Court not specified in this Order.

**Miscellaneous**

29. No party shall be responsible to another party for any use made of information that was produced and not designated as Confidential Information or Highly Confidential Information, except to the extent a party is required to perform the duties set forth in Paragraph 4 above.

30. Nothing in this Discovery Confidentiality Order shall prejudice the right of any party to oppose production of any information for lack of relevance, privilege, or any ground other than confidentiality.

31. Nothing in this Discovery Confidentiality Order shall prejudice the right of any party to seek at any time a further order modifying this Discovery Confidentiality Order.

32. In the event that a new party is added, substituted, or brought in, this Discovery Confidentiality Order will be binding on and inure to the benefit of the new party, subject to the right of the new party to seek relief from or modification of this Discovery Confidentiality Order.

33. Notice under this Discovery Confidentiality Order shall be to the parties as follows, unless this provision is modified by the parties in writing and filed with this Court: notice to Celgene shall be made to F. Dominic Cerrito, Quinn Emanuel Urquhart & Sullivan, LLP, 51 Madison Avenue, 22<sup>nd</sup> Floor, New York, NY 10010, nickcerrito@quinnmanuel.com and to Matthew Hertko, Jones Day, 77 W. Wacker Drive, Chicago, IL, 60601, mkhertko@jonesday.com; notice to Alembic shall be made to Joseph T. Jaros, Rakoczy Molino Mazzochi Siwik LLP, 6 West

Hubbard Street, Ste. 500, Chicago, IL 60654, jjaros@rmmslegal.com and to Eric Abraham, Hill Wallack LLP, 21 Roszel Road, Princeton, NJ 08540, eabraham@hillwallack.com.

34. In the event any provision of this Order is inconsistent with the Court's Local Civil Rules, the latter shall control.

IT IS SO STIPULATED AND AGREED this 7th day of April, 2022:

By: s/ Charles M. Lizza  
Charles M. Lizza  
William C. Baton  
Sarah A. Sullivan  
SAUL EWING ARNSTEIN & LEHR LLP  
One Riverfront Plaza, Suite 1520  
Newark, New Jersey 07102-5426  
(973) 286-6700  
clizza@saul.com

By: s/ Eric I. Abraham  
Eric I. Abraham  
(eabraham@hillwallack.com)  
HILL WALLACK LLP  
21 Roszel Road  
Princeton, NJ 08540  
(609) 734-6358 (telephone)

OF COUNSEL:

F. Dominic Cerrito  
Eric C. Stops  
Evangeline Shih  
Andrew S. Chalson  
Gabriel P. Brier  
Frank C. Calvosa  
Marta A. Godecki  
Brian J. Forsatz  
Nicholas A. LoCastro  
QUINN EMANUEL URQUHART &  
SULLIVAN, LLP  
51 Madison Avenue, 22nd Floor  
New York, New York 10010  
(212) 849-7000

Anthony M. Insogna  
Cary Miller, Ph.D.  
JONES DAY  
4655 Executive Drive  
San Diego, CA 92121  
(858) 314-1200

Matthew J. Hertko  
JONES DAY  
77 W. Wacker Drive  
Chicago, IL 60601  
(312) 782-3939

Of Counsel  
William Rakoczy  
(wrakoczy@rmmslegal.com)  
Deanne Mazzochi  
(dmazzochi@rmmslegal.com)  
Joseph Jaros (jjaros@rmmslegal.com)  
Matthew Anderson  
(manderson@rmmslegal.com)  
Thomas Ehrich  
(tehrich@rmmslegal.com)  
Adrienne Rose  
(arose@rmmslegal.com)  
RAKOCZY MOLINO MAZZOCHI SIWIK  
LLP  
6 West Hubbard Street, Suite 500  
Chicago, Illinois 60654  
(312) 527-2157 (telephone)

*Attorneys for Defendant/Counterclaim-  
Plaintiff Alembic Pharmaceuticals  
Limited*

*Attorneys for Plaintiff  
Celgene Corporation*

**IT IS SO ORDERED:**

---

Hon. Leda D. Wettre, U.S.M.J.

Dated: \_\_\_\_\_

**EXHIBIT A**

**CELGENE CORPORATION,**  
**Plaintiff,**

v.

**ALEMBIC PHARMACEUTICALS  
LIMITED,**

**Defendant.**

**Civil Action No. 21-20099  
(SDW)(LDW)**

**DECLARATION OF COMPLIANCE**

I, \_\_\_\_\_ do declare and state as follows:

1. I live at \_\_\_\_\_. I am employed as (state position) \_\_\_\_\_ by (state name and address of employer) \_\_\_\_\_.

2. I have read the Discovery Confidentiality Order entered in this case, a copy of which has been given to me.

3. I understand and agree to comply with and be bound by the provisions of the Discovery Confidentiality Order, including that upon receipt of any Confidential Information or Highly Confidential Information, I will be personally subject to it, and to all of its requirements and procedures.

4. I agree that I will be subject to the jurisdiction of the United States District Court for the District of New Jersey for purposes of enforcement of the Discovery Confidentiality Order.

5. I understand that unauthorized disclosure of any designated Confidential Information or Highly Confidential Information, or its use for any purpose other than this litigation, may constitute contempt of this Court and may subject me to sanctions or other remedies

that may be imposed by the Court and or potential liability in a civil action for damages by the producing party.

6. At the final termination of this litigation, I will return to counsel or destroy all documents or things consisting of or containing Confidential Information or Highly Confidential Information.

7. I declare, as provided by 28 U.S.C. Section 1746, under penalty of perjury, under the laws of the United States of America, that the foregoing is true and correct.

Executed this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_\_.  

---